{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:11:46Z","timestamp":1790367106430,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81000058"],"award-info":[{"award-number":["81000058"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The level of lipoprotein-associated phospholipase A2 (LP-PLA2) in serum is independently correlated to coronary artery diseases (CAD). The aim of the study was to determine whether LP-PLA2 activity is positively associated with the seriousness of CAD.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Amount to 1056 patients suspected of having CAD underwent coronary angiography (CAG) to determine the seriousness of CAD. According to the amount of diseased coronary branches, the 1056 patients were split into three groups: single-vessel stenosis group, multiple-vessels stenosis group (&gt; or\u2009=\u20092 diseased coronary branches),and control group (no diseased coronary branches). According to CAG results, electrocardiography, cardiac biomarker, and clinical presentation, all patients were split into four groups: acute myocardial infarction (AMI), unstable angina (UA), stable angina (SA), and control groups (excluding CAD). The activity of LP-PLA2 was compared statistically among the subgroups. Receiver operating characteristic analysis was applied to investigate the role of LP-PLA2 in evaluating the presence and seriousness of CAD.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The level of LP-PLA2 increased in line with the number of diseased coronary branches. The levels of LP-PLA2 in the AMI and UA groups were observably higher when compared with the control and SA groups. LP-PLA2 had 75.6% sensitivity and 67.3% specificity for recognizing CAD, and 53.0% sensitivity and 80.3% specificity for recognizing severe coronary artery lesions.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The activity of LP-PLA2 is positively correlated to the seriousness of CAD.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12872-020-01580-4","type":"journal-article","created":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T13:03:45Z","timestamp":1592312625000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["The relationship of lipoprotein-associated phospholipase A2 activity with the seriousness of coronary artery disease"],"prefix":"10.1186","volume":"20","author":[{"given":"Hao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3919-1417","authenticated-orcid":false,"given":"Dingguo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,16]]},"reference":[{"issue":"4","key":"1580_CR1","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1056\/NEJM200507283530425","volume":"353","author":"J Garcia de Tena","year":"2005","unstructured":"Garcia de Tena J. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;353(4):429\u201330 author reply 429-430.","journal-title":"N Engl J Med"},{"issue":"12","key":"1580_CR2","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJM200003233421202","volume":"342","author":"PM Ridker","year":"2000","unstructured":"Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836\u201343.","journal-title":"N Engl J Med"},{"issue":"21","key":"1580_CR3","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.2174\/13816128113199990307","volume":"19","author":"E Moutzouri","year":"2013","unstructured":"Moutzouri E, Tsimihodimos V, Tselepis AD. Inflammatory biomarkers and cardiovascular risk assessment. Current knowledge and future perspectives. Curr Pharm Des. 2013;19(21):3827\u201340.","journal-title":"Curr Pharm Des"},{"issue":"2","key":"1580_CR4","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.coph.2005.11.008","volume":"6","author":"CH Macphee","year":"2006","unstructured":"Macphee CH, Nelson J, Zalewski A. Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target. Curr Opin Pharmacol. 2006;6(2):154\u201361.","journal-title":"Curr Opin Pharmacol"},{"issue":"5","key":"1580_CR5","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1161\/01.ATV.0000160551.21962.a7","volume":"25","author":"A Zalewski","year":"2005","unstructured":"Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol. 2005;25(5):923\u201331.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"1580_CR6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ijcard.2012.09.210","volume":"165","author":"D Tousoulis","year":"2013","unstructured":"Tousoulis D, Papageorgiou N, Androulakis E, Stefanadis C. Lp-PLA2--a novel marker of atherosclerosis: to treat or not to treat? Int J Cardiol. 2013;165(2):213\u20136.","journal-title":"Int J Cardiol"},{"issue":"7","key":"1580_CR7","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1161\/01.CIR.0000116763.91992.F1","volume":"109","author":"CM Ballantyne","year":"2004","unstructured":"Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the atherosclerosis risk in communities (ARIC) study. Circulation. 2004;109(7):837\u201342.","journal-title":"Circulation"},{"issue":"23","key":"1580_CR8","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1093\/eurheartj\/ehs132","volume":"33","author":"L Lind","year":"2012","unstructured":"Lind L, Simon T, Johansson L, Kotti S, Hansen T, Machecourt J, Ninio E, et al. Circulating levels of secretory- and lipoprotein-associated phospholipase A2 activities: relation to atherosclerotic plaques and future all-cause mortality. Eur Heart J. 2012;33(23):2946\u201354.","journal-title":"Eur Heart J"},{"issue":"1","key":"1580_CR9","doi-asserted-by":"publisher","first-page":"e83393","DOI":"10.1371\/journal.pone.0083393","volume":"9","author":"M Katan","year":"2014","unstructured":"Katan M, Moon YP, Paik MC, Wolfert RL, Sacco RL, Elkind MS. Lipoprotein-associated phospholipase A2 is associated with atherosclerotic stroke risk: the northern Manhattan study. PLoS One. 2014;9(1):e83393.","journal-title":"PLoS One"},{"issue":"18","key":"1580_CR10","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1056\/NEJMoa1315878","volume":"370","author":"S Investigators","year":"2014","unstructured":"Investigators S, White HD, Held C, Stewart R, Tarka E, Brown R, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. 2014;370(18):1702\u201311.","journal-title":"N Engl J Med"},{"issue":"10","key":"1580_CR11","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1001\/jama.2014.11061","volume":"312","author":"ML O'Donoghue","year":"2014","unstructured":"O'Donoghue ML, Braunwald E, White HD, Lukas MA, Tarka E, Steg PG, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. Jama. 2014;312(10):1006\u201315..","journal-title":"Jama"},{"issue":"8","key":"1580_CR12","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1007\/s00059-019-04862-6","volume":"44","author":"S Silber","year":"2019","unstructured":"Silber S. ESC guidelines 2019 on chronic coronary syndrome (CCS, previously \"stable coronary artery disease\") : What is new? What is particularly important? Herz. 2019;44(8):676\u201383.","journal-title":"Herz"},{"issue":"1","key":"1580_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12872-015-0001-9","volume":"15","author":"A Cai","year":"2015","unstructured":"Cai A, Li G, Chen J, Li X, Li L, Zhou Y. Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese population. BMC Cardiovasc Disord. 2015;15(1):14.","journal-title":"BMC Cardiovasc Disord"},{"issue":"5","key":"1580_CR14","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/MOL.0b013e3283307c16","volume":"20","author":"RL Wilensky","year":"2009","unstructured":"Wilensky RL, Macphee CH. Lipoprotein-associated phospholipase a (2) and atherosclerosis. Curr Opin Lipidol. 2009;20(5):415\u201320.","journal-title":"Curr Opin Lipidol"},{"issue":"5","key":"1580_CR15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1155\/2013\/432136","volume":"34","author":"A Cai","year":"2013","unstructured":"Cai A, Zheng D, Qiu R, Mai W, Zhou Y. Lipoprotein-associated phospholipase A2 (Lp-PLA (2)): a novel and promising biomarker for cardiovascular risks assessment. Dis Markers. 2013;34(5):323\u201331.","journal-title":"Dis Markers"},{"issue":"17","key":"1580_CR16","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.jacc.2007.11.079","volume":"51","author":"ER Mohler 3rd","year":"2008","unstructured":"Mohler ER 3rd, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2008;51(17):1632\u201341.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"1580_CR17","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1253\/circj.CJ-12-0813","volume":"77","author":"H Daida","year":"2013","unstructured":"Daida H, Iwase T, Yagi S, Ando H, Nakajima H. Effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity in Japanese dyslipidemic patients, with exploratory analysis of a PLA2G7 gene polymorphism of Val279Phe. Circ J. 2013;77(6):1518\u201325.","journal-title":"Circ J"},{"issue":"9725","key":"1580_CR18","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1016\/S0140-6736(10)60319-4","volume":"375","author":"PLASC Lp","year":"2010","unstructured":"Lp PLASC, Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, et al. Lipoprotein-associated phospholipase a (2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010;375(9725):1536\u201344.","journal-title":"Lancet"},{"issue":"5","key":"1580_CR19","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.ahj.2006.01.011","volume":"152","author":"HT May","year":"2006","unstructured":"May HT, Horne BD, Anderson JL, Wolfert RL, Muhlestein JB, Renlund DG, Clarke JL, Kolek MJ, Bair TL, Pearson RR, et al. Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death. Am Heart J. 2006;152(5):997\u20131003.","journal-title":"Am Heart J"},{"issue":"21","key":"1580_CR20","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1161\/CIRCULATIONAHA.106.671420","volume":"115","author":"S Lavi","year":"2007","unstructured":"Lavi S, Mcconnell JP, Rihal CS, Prasad A, Mathew V, Lerman LO, et al. Local production of lipoprotein-associated phospholipase A2 and Lysophosphatidylcholine in the coronary circulation association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation. 2007;115(21):2715\u201321.","journal-title":"Circulation"},{"issue":"2","key":"1580_CR21","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.atherosclerosis.2007.02.012","volume":"196","author":"M Iwase","year":"2008","unstructured":"Iwase M, Sonoki K, Sasaki N, Ohdo S, Higuchi S, Hattori H, et al. Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment. Atherosclerosis. 2008;196(2):931\u20136.","journal-title":"Atherosclerosis"},{"issue":"5","key":"1580_CR22","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.ahj.2011.01.017","volume":"161","author":"JS Berger","year":"2011","unstructured":"Berger JS, Ballantyne CM, Davidson MH, Johnson JL, Tarka EA, Lawrence D, et al. Peripheral artery disease, biomarkers, and darapladib. Am Heart J. 2011;161(5):972\u20138.","journal-title":"Am Heart J"},{"issue":"18","key":"1580_CR23","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1056\/NEJMoa1315878","volume":"370","author":"P Buszman","year":"2014","unstructured":"Buszman P. Darapladib for preventing ischemic events in stable coronary heart disease &mdash; NEJM. New Eng J Med. 2014;370(18):1702\u201311.","journal-title":"New Eng J Med"},{"issue":"7","key":"1580_CR24","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1194\/jlr.M300086-JLR200","volume":"44","author":"S Blankenberg","year":"2003","unstructured":"Blankenberg S, Stengel D, Rupprecht HJ, Bickel C, Meyer J, Cambien F, et al. Plasma PAF-acetylhydrolase in patients with coronary artery disease results of a cross-sectional analysis. J Lipid Res. 2003;44(7):1381\u20136.","journal-title":"J Lipid Res"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-020-01580-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-020-01580-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-020-01580-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T23:16:03Z","timestamp":1623798963000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-020-01580-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,16]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1580"],"URL":"https:\/\/doi.org\/10.1186\/s12872-020-01580-4","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,16]]},"assertion":[{"value":"27 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All the research was approved by the institutional review board of Ethical Committee of Nanjing Medical University. And all the enrolled subjects provided written informed consent. The administrative permissions were acquired by our team to access the data we used in our research.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Signed consents were obtained from the enrolled patients to use their clinical information and sequencing data for publications.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"295"}}